New class of antigen-presenting immune cell identified by researchers
A new kind of dendritic cell has been discovered by researchers and could play a role presenting antigens to other immune cells during respiratory virus infections.
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
A new kind of dendritic cell has been discovered by researchers and could play a role presenting antigens to other immune cells during respiratory virus infections.
Researchers have found that molecules from ticks called Evasins have the potential to halt cytokine storms, the leading cause of COVID-19 fatalities.
Bioassays and thin-layer chromatography has been used by scientists to analyse molecules in plant extracts as a fast and cost-effective method for identifying new drug compounds.
A new compound named L1 has demonstrated success in mice, by reducing neuroinflammation and decreasing the levels of amyloid plaques, showing potential as an Alzheimer's treatment.
Tested on plaque reducing assays, researchers have identified a lead candidate multivalent carbohydrate-binding module for the treatment of COVID-19.
After analysing the genomic diversity in SARS-CoV-2 by screening over 7,500 viruses from infected patients, researchers have offered clues for COVID-19 drug development.
James Graham from Recce Pharmaceuticals discusses how a new class of synthetic antibiotics could be the key to preventing the spread of antibiotic resistance.
A molecule called microRNA-744, which influences inflammation, has been revealed by researchers as a new drug target for Sjögren's Syndrome.
Researchers have shown that the activation sequence the SARS-CoV-2 S protein is cleaved by the cellular enzyme furin which is also required for the infection of lung cells.
An antibody that neutralises both SARS-CoV and SARS-CoV-2 in cell cultures has been discovered by researchers and could be used to treat COVID-19.
According to a new study, treatments for COVID-19 should focus on cytokines and T-cell counts and their function, rather than patient respiratory function.
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
A group of researchers has used cryo-EM to discover the structure of the remdesivir-bound RNA complex of SARS-CoV-2 and explain how the drug inhibits COVID-19 viral replication.
Researchers have uncovered the structure of nonribosomal peptide synthetases (NRPSs), an important ingredient in drug production.
According to researchers, ACE2 receptors disappear from lung cells during COVID-19, allowing small blood vessels to leak at the site of infection, presenting a new drug target.